About EDGAR Online | Login
 
The following is an excerpt from a 10QSB SEC Filing, filed by LIBERTY MINT LTD on 8/14/2000.
Next Section Next Section Previous Section Previous Section
AKESIS PHARMACEUTICALS, INC. - 10QSB - 20000814 - CASH_FLOW

LIBERTY MINT, LTD. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

[Unaudited - See Accountants' Review Report]

                                                             For the Six
                                                             Months Ended
                                                             December 31,
                                                       _______________________
                                                            2000      1999
                                                       ______________________
Cash Flows Provided by Operating Activities:
  Net loss                                            $(231,972)   $ (227,551)
                                                       ______________________
  Adjustments to reconcile net loss
    to net cash used by operating activities:
  Depreciation and amortization                          11,577           122
  Non-cash expenses, including stock issued for
    services & interest expense                         239,272             -
   Changes in assets and liabilities:
     Decrease in accounts receivable                    130,871         1,776
     (Increase) decrease in inventory                   634,258       (95,846)
     Decrease in prepaid expenses                        (7,804)      (18,000)
     (Increase) in other assets                             207             -
     Increase in accounts payable                        76,425        73,704
     (Decrease) in factoring advances                   (85,710)            -
     (Decrease) in accrued expenses                    (298,865)            -
     (Decrease) in customer deposits                   (716,486)            -
     (Decrease) in liabilities of discontinued
       operations                                       (16,802)     (269,988)
                                                        ______________________
       Net Cash (Used) by Operating Activities         (265,029)     (535,783)
                                                        ______________________
Cash Flows Provided by Investing Activities:
  Purchases of property and equipment                  (177,569)            -
                                                        ______________________
       Net Cash (Used) by Investing Activities         (177,569)            -
                                                        ______________________
Cash Flows Provided by Financing Activities:
  Proceeds from Issuance of common stock                      -       538,396
  Decrease in stock subscription receivable             125,000             -
  Increase in notes payable - related party             271,973             -
                                                        ______________________
       Net Cash Provided by Financing Activities        396,973       538,396
                                                        ______________________
Net Increase (Decrease) in Cash and Cash Equivalents    (45,625)        2,613

Cash and Cash Equivalents at Beginning of Period         53,858        52,223
                                                        ______________________
Cash and Cash Equivalents at End of Period             $  8,233      $ 54,836
                                                        ________________________